GLP-1 medications, known as glucagon-like peptide-1 receptor agonists, have gained significant popularity in recent years, with an estimated one in eight Americans currently using them. These drugs are primarily recognized for their effectiveness in managing diabetes and aiding weight loss. Research is ongoing to explore additional potential uses for these medications. However, the rapid adoption of GLP-1s has raised various questions and concerns among healthcare professionals and patients alike.
William Brangham reports for PBS NewsHour that the drugs help regulate blood sugar by stimulating insulin release. The first GLP-1 drug for diabetes was developed in the 1990s, inspired by a molecule found in the Gila monster's venom. The weight loss benefits of GLP-1s were first recognized in 2014, and it was initially believed that these effects originated in the gut. However, it has since been determined that the drugs primarily reduce appetite through brain mechanisms, leading to significant weight loss for some patients.
Patients have reported losing up to 25% of their body weight while also experiencing other health benefits, such as reduced inflammation and improved cardiovascular health. Some researchers are investigating whether GLP-1s could also have applications in treating cancer and other conditions, as users have reported improvements in long COVID symptoms, arthritis, and irritable bowel syndrome.
Despite these benefits, there are notable drawbacks, including high costs and side effects such as nausea and diarrhea. Studies indicate that up to 75% of individuals who start taking GLP-1s discontinue use within a year, often regaining lost weight. Additionally, there have been rare reports of serious side effects, including eye damage. Legal actions have been initiated against drug manufacturers over inadequate warnings regarding these risks.
The cost of GLP-1s is a significant concern, with some patients facing monthly expenses exceeding $1,000 without insurance coverage. Government initiatives have aimed to reduce costs, with some patients able to access medications for as low as $50 per month, although access remains inconsistent.
Questions persist regarding the long-term economic implications of widespread GLP-1 use, including whether current spending on these drugs could reduce future healthcare costs associated with chronic diseases. The potential global market for GLP-1 medications could reach $200 billion by 2030. As the series continues, PBS NewsHour will address issues related to access, treatment of addiction, and the cultural impact of these medications in a society focused on appearance.
This report is part of a new series titled "GLP-1s: Reshaping America," with further insights to be shared in upcoming segments.